From January 1, 2001 through December 31, 2002, the number of rizatriptan, sumatriptan, and zolmitriptan tablets dispensed was assessed using three administrative claims databases. Oral triptan costs were estimated using 2002 wholesale acquisition costs. The annualized number of tablets dispensed was, on average, significantly less for rizatriptan versus sumatriptan (9.6-10.7; P < .001) and zolmitriptan (2.4-5.5; P < .001). Per-patient oral triptan costs were lower for rizatriptan versus sumatriptan ($244-$305 less) and zolmitriptan ($62-$126 less). Rizatriptan was associated with lower tablet utilization compared with patients who were prescribed sumatriptan and zolmitriptan.
|Original language||English (US)|
|Journal||Managed care interface|
|State||Published - Nov 1 2005|
ASJC Scopus subject areas
- Health Policy